ClinicalTrials.gov
ClinicalTrials.gov Menu

Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03252431
Recruitment Status : Recruiting
First Posted : August 17, 2017
Last Update Posted : October 3, 2018
Sponsor:
Information provided by (Responsible Party):
Generon (Shanghai) Corporation Ltd.

Brief Summary:
This is a randomized, multi-center, single dose, open-label and Neulasta controlled phase 3 study to evaluate the efficacy and safety of F-627 in women with Stage I - III invasive breast cancer receiving chemotherapy treatment.

Condition or disease Intervention/treatment Phase
Breast Cancer Neutropenia Drug: F-627 Drug: Neulasta Phase 3

Detailed Description:

This is a Phase III, global, two arm, open label clinical study will randomize approximately 400 female subjects (approximately 200 per arm) with Stage I - III invasive breast cancer who are to receive neoadjuvant or adjuvant myelotoxic TC chemotherapy treatment (docetaxel + cyclophosphamide, 75 and 600 mg/m2, respectively). Subjects in this study will be those who are scheduled to undergo at least four 21-day cycles of chemotherapy treatment. Subjects may be scheduled for more than 4 cycles of chemotherapy; however, study participation will be limited to a subject's first 4 cycles.

The primary objective of this study will be to evaluate the efficacy of F-627 given as a single fixed dose (20 mg) pre-filled syringe as compared to Neulasta® standard dosing (6 mg) in the first chemotherapy cycle. The primary endpoint will be the duration of grade 4 (severe) neutropenia - the number of days in which the patient has had an absolute neutrophil count (ANC <0.5 x 10^9/L) observed in chemotherapy cycle 1.

Approximately 24 hours after chemotherapy completion in each cycle (Day 2 of the cycle), subjects will receive one of the following treatments:

Arm 1: F-627, 20 mg fixed dose pre-filled syringe, administered on Day 2 of each of 4 chemotherapy cycles.

Arm 2: 6 mg fixed dose Neulasta®, administered on Day 2 of each of 4 chemotherapy cycles Randomization will occur in an equal ratio (1:1) using a central randomization system (IWRS) on Day 1 of the study, the day of chemotherapy administration for the first chemotherapy cycle.

This study is open-label, however, study drug injections are to be administered separately by qualified study personnel to allow study investigators to remain blinded and perform study assessments without knowledge of treatment assignment.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 400 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III, Randomized, Multi-Centre, Open-Label, Fixed Dose, Neulasta® Active-Controlled Clinical Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Actual Study Start Date : February 28, 2018
Estimated Primary Completion Date : September 30, 2019
Estimated Study Completion Date : September 30, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: F-627
F-627, 20 mg fixed dose pre-filled syringe, administered on Day 2 of each of 4 chemotherapy cycles.
Drug: F-627
single dose pre-filled syringe

Active Comparator: Neulasta
6 mg fixed dose Neulasta®, administered on Day 2 of each of 4 chemotherapy cycles
Drug: Neulasta
single dose pre-filled syringe
Other Name: pegfilgrastim




Primary Outcome Measures :
  1. Duration in days of grade 4 neutropenia in chemotherapy cycle 1 [ Time Frame: The first of 4, 21-day chemotherapy cycles (average 3 weeks) ]
    The primary endpoint is the duration of grade 4 (severe) neutropenia (ANC < 0.5 x 109/L) defined as the number of days in which the subject has had an ANC < 0.5 × 109/L during cycle 1 of their chemotherapy treatment.


Secondary Outcome Measures :
  1. Duration in days of use of intravenous antibiotic [ Time Frame: across all 4 chemotherapy cycles (average 84 days) ]
    The duration of use of intravenous (IV) antibiotics (total across all chemotherapy cycles).

  2. Duration in days of hospitalization [ Time Frame: across all 4 chemotherapy cycles (average 84 days) ]
    The duration in days of patients been hospitalized for febrile neutropenia (FN) or any infection. Febrile neutropenia is defined as a single oral temperature of ≥38.3°C (101°F) or a temperature of >38.0°C (100.4°F) sustained for >1 hour and ANC <0.5 x 10^9/L on the same day.

  3. The incidence of grade 4 neutropenia for chemotherapy cycle 1 [ Time Frame: The first of 4, 21-day chemotherapy cycles (average 3 weeks) ]
    The incidence of grade 4 neutropenia for chemotherapy cycle 1

  4. The incidence of febrile neutropenia [ Time Frame: across all 4 chemotherapy cycles (average 84 days) ]
    The incidence of febrile neutropenia, considering all chemotherapy cycles.

  5. The incidence of hospitalization for febrile neutropenia or any infection [ Time Frame: across all 4 chemotherapy cycles (average 84 days) ]
    The incidence of hospitalization for febrile neutropenia or any infection, considering all chemotherapy cycles.

  6. The incidence of use of IV antibiotics [ Time Frame: across all 4 chemotherapy cycles (average 84 days) ]
    The incidence of use of IV antibiotics, considering all 4 chemotherapy cycles.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 74 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Show evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the trial.
  2. Females ≥18 years of age and <75 years of age.
  3. Diagnosed with Stage I-III breast cancer.
  4. Subject is scheduled to undergo 4 cycles of neoadjuvant or adjuvant TC chemotherapy (docetaxel, cyclophosphamide, 75, 600 mg/m2, respectively).
  5. ECOG Performance status of ≤2.
  6. WBC count ≥4.0 × 109/L, hemoglobin ≥11.5 g/dL and a platelet count ≥150 × 109/L.
  7. Demonstrate adequate renal, hepatic, and cardiac function (liver function tests [alanine aminotransferase {ALT}, aspartate aminotransferase {AST}, alkaline phosphatase, and total bilirubin]) should be less than 2.5x the upper limits of normal (ULN). Serum creatinine should be less than 1.7x ULN.
  8. All subjects must agree to use at least one of the following types of contraception: intrauterine device, implantable progesterone device, progesterone intramuscular injection, or oral contraceptive, which has been started at least one month prior to visit one and will continue for the duration of the trial. The contraceptive patch or condom use with spermicide is also acceptable forms of contraception as long as they will be used continually throughout the duration of the trial.

Exclusion Criteria:

  1. Subject is <18 or ≥75 years of age.
  2. Disease progression has occurred while receiving a taxane regimen.
  3. Subject has undergone radiation therapy within 4 weeks of enrollment.
  4. Subject has undergone bone marrow or stem-cell transplantation.
  5. Subject has a history of prior malignancy other than breast cancer that is NOT in remission.
  6. Subjects that have used G-CSF or any other drug that may potentiate the release of neutrophils (i.e., lithium) within 6 weeks of the screening period are excluded.
  7. Subject has had chemotherapy within 180 days of screening.
  8. Subject has documented congestive heart failure, cardiomyopathy or myocardial infarction by clinical diagnosis, electrocardiogram (ECG) test, or any other relevant test.
  9. History of alcohol or drug abuse that would interfere with the ability to be compliant with the study procedure.
  10. Unwillingness to participate in the study.
  11. Any underlying medical condition that, in the Investigator's opinion, would make the administration of study drug hazardous to the patient or that would obscure the interpretation of adverse events.
  12. Receiving other investigational drugs or biologics within 1 month or five half lives of enrollment (if known), which ever is less.
  13. Any condition, which can cause splenomegaly.
  14. Chronic constipation or diarrhea, irritable bowel syndrome, inflammatory bowel disease.
  15. ALT, AST, alkaline phosphatase, total bilirubin ≥2.5x ULN.
  16. Subject with active infection, or known to be infected with chronic active Hepatitis B within the last 1 year (unless shown at the time of study entry to be Hepatitis B antigen negative), or having any history of Hepatitis C.
  17. Women who are pregnant or breast-feeding.
  18. Subject known to be seropositive for HIV, or who have had an AIDS defining illness or a known immunodeficiency disorder.
  19. Subject with a history of tuberculosis or exposure to tuberculosis. Patients that have received a prior chest X-ray for suspicion of tuberculosis are also excluded unless they have been confirmed to be PPD negative or they had latent tuberculosis that has been previously treated.
  20. Subjects with Sickle Cell disease
  21. Subjects with known hypersensitivity to E.coli derived proteins' pegfilgrastim' filgrastim, or any other component of the study drug.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03252431


Contacts
Contact: William L Daley, MD 1 973-641-0367 wldaley@generonbiomed.com

Locations
United States, California
University of California Los Angeles (UCLA) - Jonsson Comprehensive Cancer Center (JCCC) Recruiting
Los Angeles, California, United States, 90095
Contact: John Glaspy, MD         
Sponsors and Collaborators
Generon (Shanghai) Corporation Ltd.

Responsible Party: Generon (Shanghai) Corporation Ltd.
ClinicalTrials.gov Identifier: NCT03252431     History of Changes
Other Study ID Numbers: GC-627-05
First Posted: August 17, 2017    Key Record Dates
Last Update Posted: October 3, 2018
Last Verified: October 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Breast Neoplasms
Neutropenia
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Agranulocytosis
Leukopenia
Leukocyte Disorders
Hematologic Diseases